Press Release Source: Aethlon Medical, Inc.

On 8:00 am EST, Tuesday November 10, 2009

Aethlon Medical Inc.

SAN DIEGO, Nov. 10 - Aethlon Medical, Inc. (OTC Bulletin Board: AEMD - News) announced today that Dr. Douglas Taylor has joined the Science Advisory Board of Exosome Sciences, Inc. (ESI). Dr. Taylor is credited with the discovery of tumor-secreted exosomes and is a leading published author on the topic. ESI, a wholly owned subsidiary of Aethlon Medical, was recently formed to leverage the discovery that the Hemopurifier , a medical device being advanced as an adjunct therapy for Hepatitis-C (HCV) and other viral pathogens, is capable of capturing exosomes secreted by solid tumors, lymphomas, and leukemia to suppress the immune response in cancer patients. The targeted removal of circulating exosomes to inhibit cancer related immune suppression could increase patient responsiveness to both immunotherapy and chemotherapy.

Javulation Coffee - http://www.myjavafit.com/ ABOUT Nebulastocks.com Nebulastocks is a leading stock website that provides FREE newsletters on stocks that are potential huge movers and also tracks micro cap stocks that could be undervalued by the market. Nebulastocks.com strives to provide an edge to Traders and Investors with its FREE newsletter service.

Nebulastocks.com is an independent electronic publication that provides information on selected publicly traded companies. Nebulastocks.com s not a registered investment advisor or broker-dealer. Nebulastocks.com affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.

CONTACT: Nebulastocks.com WWW: http://www.nebulastocks.com/

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

"We are honored to have Dr. Taylor become the first member of our ESI science advisory board," stated Aethlon Chairman and Chief Executive Officer, Jim Joyce. "As we assemble of team of thought leaders in the emerging exosome field, Dr. Taylor will provide important guidance specific to the treatment and diagnoses of ovarian cancer," concluded Joyce.

About Dr. Douglas Taylor

Dr. Douglas Taylor is currently Professor and Vice Chair for Research in the Department of Obstetrics, Gynecology, and Women's Health at the University of Louisville School of Medicine. He joined the University of Louisville School of Medicine faculty with a joint appointment in the Departments of Obstetrics and Gynecology and Immunology in April 1992. He received his BS for the University of Richmond with a double major in Chemistry and Biology. He earned his Ph.D. for the Bowman Gray School of Medicine of Wake Forest University in 1982. His previous employment experience was as postdoctoral fellow in Immunology at Boston University School of Medicine. In 1988, he joined became Director of Research in the Department of Surgical Oncology at the Fox Chase Cancer Center in Philadelphia. Due to his association with clinical departments, he has extensive experience in development of diagnostic clinical assay systems. In 1979, Dr. Taylor discovered the phenomenon of exosomal shedding and has developed his research project around exosome-based diagnostic markers. He currently has 3 patents submitted on exosome-based diagnostics for cancer and has additional disclosures on technologies associated with the diagnosis of adverse pregnancy outcomes. He has authored over 80 peer-viewed publications and currently has funding from the NIH, the Department of Defense Ovarian Cancer Program, and the March of Dimes.

About Aethlon Medical

Aethlon Medical creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our Hemopurifier(R) represents the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The Hemopurifier(R) seeks to improve Hepatitis-C treatment outcomes and serves as a broad-spectrum treatment countermeasure against bioterror and pandemic threats. Additional information regarding Aethlon Medical can be accessed online at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier(R) to reduce viral loads and other disease conditions or to identify disease conditions such as cancer, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

    Contacts:

    RedChip Companies, Inc.
    Jon Cunningham
    1-800-733-2447, Ext. 107
    Jon@redchip.com

    Jim Joyce
    Chairman, CEO
    858.459.7800 x301
    jj@aethlonmedical.com

    Jim Frakes
    Senior VP Finance
    858.459.7800 x300
    jfrakes@aethlonmedical.com

SOURCE Aethlon Medical, Inc.

http://www.aethlonmedical.com

The research goal is to discover common biomarkers, including dormant viruses that might lead to a diagnostic product able to identify athletes with an increased susceptibility to suffer from CTE. Such a test could help distinguish those who should be precluded from participating in football and other activities with a high risk for head trauma, Aethlon Medical said.

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

"This collaboration is near and dear to my heart as CTE was identified in Tom McHale, (Click Here for NY Times Story) a friend and former high school and college teammate who died at the age of 45 last year," stated Aethlon Chairman and CEO, Jim Joyce. "Additionally, we have the opportunity to showcase that the scientific advancements underlying our infectious disease and cancer treatment devices provide the basis for new products to discover the presence of biomarkers associated with various medical conditions," concluded Joyce. Aethlon Medical also disclosed it will provide SLI with a $25,000 unrestricted educational grant to support educational outreach.

"Aethlon Medical has presented a wonderful opportunity to advance CTE research," said SLI co-founder Chris Nowinski, who is also a Co-Director at the CSTE. "Historically, a small number of viruses have been found to lead to later life neurodegeneration characterized by tau protein deposition, including encephalitis lethargica (also known as von Economo encephalitis and the "sleeping sickness"), and subacute sclerosing panencephalitis (SSPE), caused by a defective measles virus. We also appreciate Aethlon's support in helping us continue our educational and prevention efforts."

Most recently, CTE research advanced by CSTE and SLI researchers has been broadly covered in the media, including; 60 Minutes, CNN, The New York Times, New Yorker Magazine, USA Today, HBO, and ESPN. Last week, four CSTE and SLI representatives testified before a congressional judiciary committee investigating the impact of head injuries sustained by NFL players.

About The Sports Legacy Institute

Sports Legacy Institute is a 501(c)(3) nonprofit corporation founded in 2007 to solve the sports concussion crisis. SLI is dedicated to education, prevention, treatment, and research on the effects of concussions and other brain injuries in athletes and the military. SLI partnered with Boston University School of Medicine to form the Center for the Study of Traumatic Encephalopathy in 2008. Additional information can be accessed at: www.sportslegacy.org

About The Center for the Study of Traumatic Encephalopathy (CSTE)

The CSTE was created in 2008 as a collaborative venture between Boston University School of Medicine and Sports Legacy Institute (SLI). The mission of the CSTE is to conduct state-of-the-art research of Chronic Traumatic Encephalopathy, including its neuropathology and pathogenesis, the clinical presentation and course, the genetics and other risk factors for CTE, and ways of preventing this cause of dementia. Additional information can be accessed online at: www.bu.edu/alzresearch/research/encephalopathy/

About Chronic Traumatic Encephalopathy

Chronic Traumatic Encephalopathy (CTE) is a progressive degenerative disease of the brain found in athletes (and others) with a history of repetitive concussions. CTE has been known to affect boxers since the 1920s. However, recent reports have been published of neuropathologically confirmed CTE in retired professional football players and wrestlers who have a history of head trauma. This trauma, which includes multiple concussions and subconcussive blows to the head, triggers progressive degeneration of the brain tissue, including the build-up of an abnormal protein called tau. These changes in the brain can begin months, years, or even decades after the last concussion or end of active athletic involvement. The brain degeneration is associated with memory loss, confusion, impaired judgment, paranoia, impulse control problems, aggression, depression, and, eventually, progressive dementia.

About Aethlon Medical

Aethlon Medical creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our Hemopurifier(R) represents the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The Hemopurifier(R) seeks to improve Hepatitis-C treatment outcomes and serves as a broad-spectrum treatment countermeasure against bioterror and pandemic threats. Additional information regarding Aethlon Medical can be accessed online at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier(R) to reduce viral loads and other disease conditions or to identify disease conditions such as Chronic Traumatic Encephalopathy, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

    Contacts:

    RedChip Companies, Inc.
    Jon Cunningham
    1-800-733-2447, Ext. 107
    Jon@redchip.com

    Jim Joyce
    Chairman, CEO
    858.459.7800 x301
    jj@aethlonmedical.com

    Jim Frakes
    Senior VP Finance
    858.459.7800 x300
    jfrakes@aethlonmedical.com

SOURCE Aethlon Medical, Inc.

http://www.aethlonmedical.com